* Champions Oncology Inc CSBR.OQ CSBR.O is expected
to show a
rise in quarterly revenue when it reports results on July 21.
* The Baltimore Maryland-based company is expected to
report a
20.4% increase in revenue to $12.724 million from $10.57 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Champions Oncology
Inc is
for earnings of 3 cents per share. For the same quarter last
year, the company reported a loss of 4 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Champions
Oncology Inc is $14, above its last closing price of $8.20.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jan. 31 2022 0.02 0.03 0.05 Beat 100
Oct. 31 2022 0.01 0.01 0.02 Beat 300
Jul. 31 2021 0.01 0.01 -0.01 Missed -200
Apr. 30 2021 0.00 0.00 -0.04 Missed
Jan. 0.00 0.01 0.05 Beat 649.6
31 2021
Oct. 31 2020 0.00 0.00 0.00 Met
Jul. 31 2020 0.02 0.02 0.01 Missed -50
Apr. 30 2020 0.02 -0.14 Missed -1,033
.3
This summary was machine generated July 19 at 20:50 GMT. All
figures in US dollars unless otherwise stated